View more on these topics

Woodford and Fundsmith among most sold funds in January


Star fund managers Neil Woodford and Terry Smith ran some of the most sold funds in January, according to Charles Stanley Direct.

Only the Axa Framlington Biotech fund was more sold over the month, while the Artemis Global Income was the best selling.

The Woodford UK Equity Income fund suffered a “disappointing” 2016 delivering investors returns of just 3.3 per cent compared to 16.8 per cent in the FTSE All Share index.

Woodford has previously admitted his clients’ resolve would have been tested over the period, particularly with stocks such as Capita and Next not performing as well as expected.

Fundsmith delivered good returns for the full year, but underperformed in the second half of the year, a period when it saw large inflows from investors seeking global exposure following Brexit.

The Fundsmith Equity fund returned 12.3 per cent between 24 June, when the Brexit vote was revealed, and the end of the year, compared to 21.5 per cent in the MSCI World index, FE data shows.

The IA Global sector returned 19.2 per cent over the period.

Passives featured heavily in the top 10 most bought funds in January, with four Vanguard products, including three from the LifeStrategy range, as well as the Legal & General US Index fund and the Fidelity Index World.

However, the Vanguard LifeStrategy 80% Equity and Legal & General US Index also both featured in the most sold list alongside two other passive products; the Vanguard FTSE All Share Index and Global Small-Cap funds.

The Artemis Global Income made the top 10 for a third month in a row and has benefited from its bias towards more economically sensitive parts of the market, in contrast to Fundsmith’s bond proxies bias.

Morgan says the Axa Framlington Biotech fund has suffered due to volatility in the sector.

The US health care system seems to be on course for reform, and investors may remain cautious until there is more clarity on the impact of President Donald Trump’s legislative priorities on prescription drug prices,” Morgan says.

The top ten fund buys:

  • Artemis Global Income
  • CF Woodford Equity Income
  • Fidelity Index World
  • Fundsmith Equity
  • JOHCM UK Equity Income
  • Legal & General US Index
  • Vanguard FTSE Developed World Ex UK Equity
  • Vanguard LifeStrategy 100% Equity
  • Vanguard LifeStrategy 60% Equity
  • Vanguard LifeStrategy 80% Equity

The top ten fund sells

  • AXA Framlington Biotech
  • CF Woodford Equity Income
  • Fundsmith Equity
  • Investec Global Gold
  • Legal & General US Index
  • Smith & Williamson Global Gold & Resources
  • Standard Life Investments Global Absolute Return Strategies
  • Vanguard FTSE All Share Index
  • Vanguard Global Small-Cap
  • Vanguard LifeStrategy 80% Equity

For more investment news click here



Woodford confirms higher income fund launch

Woodford Investment Management has confirmed it will launch a higher income fund. The company confirmed in a statement that it intends to launch the CF Woodford Income Focus fund in March 2017, with a fixed-offer period. Further dates will be confirmed in due course. Money Marketing sister title Fund Strategy understands the fund, to be managed by […]


Woodford triples profits to £35m

Woodford Investment Management has reported its yearly profits have tripled to £35.4m from £12m. The boutique asset manager had total revenue of £58.3m as of 31 March, up from £27.4m a year ago, mostly due to management fees, according to accounts from Companies House for the second year after the firm launched. Total operating expenses […]


The Govt’s IHT warning on pension transfers

A recent case has highlighted a controversial approach HM Revenue & Customs applies that can subject a member of a registered pension scheme to unexpected inheritance tax charges following a transfer. The situation can arise if the member transfers their benefits when they know their life expectancy is impaired and they die within the following two […]

What triggers the MPAA?

Jim Grant – Senior Product Insight & Technical Support Analyst There’s sometimes confusion around what triggers the money purchase annual allowance. Find out what does and what doesn’t trigger the MPAA. The money purchase annual allowance (MPAA) is a reduced annual allowance that can apply to contributions to defined contribution (DC) schemes. The following table […]


News and expert analysis straight to your inbox

Sign up


There are 2 comments at the moment, we would love to hear your opinion too.

  1. It is brilliant that a headline could actually mean the exact opposite but in this instance it is ‘true’ – most ditched. Then it is doubly brilliant that investors or advisers are ditching the funds after one poor outcome – embarrassing that they either supported them in the first place or that they quit at the first moment of poor performance. What sort of industry are we creating guys? We have neither incidentally but that is not for reasons of under-performance but for other reasons!

  2. Fundsmith has been excellent. Looking at the complete portfolio of Fundsmith stocks it is worrying that many have not been in fashion since Trump. It is almost as though the excellent basis for Stock selection up till Trump is not the one working now. How soon the previous fashion will reestablish it itself is not clear. As I have heard Volatility is low but uncertainty is high and a shorter term go with the flow investing fashion may be establishing itself.

Leave a comment